A453 period: In the period of four as well as eigth -weeks course of treatment with imiquimod 5% cream, therapy resulted in significantly higher chance of achieving complete clearance. Patients treated with imiquimod more frequently achieved clearance level higher than 75% of baseline actinic keratoses compared with the subject in vehicle group. Adverse events were more frequently recorded within the group of subjects who received imiquimod in comparison with vehicle group. The chance of experiencing local skin reaction such as erythema, flaking/scaling/dryness, scabbing/crusting, oedema, vesicles, erosin/ulceration was significantly higher in experimental group. Imiquimod five percent cream versus vehicle in long time period: Imiquimod 5% cream used 3 times a week for 24 weeks was an effective treatment for actinic keratosis measured by the probability of achieving complete clearance and partial clearance rate (more than 75% reduction in baseline lesions). Frequency of adverse events and local skin reactions was higher during the imiquimod treatment in comparison with placebo. Imiquimod five percent cream versus vehicle in patient with solid organ transplants: Treatment with imiquimod 5% cream for 24 weeks in kidney, heart and liver transplant patients resulted in significantly higher probability of achieving complete and partial clearance rates of actinic keratoses. There were no significant differences in incidence of adverse events between groups. CONCLUSIONS: Imiquimod five percent cream appears to be effective and safe alternative therapy for the treatment of actinic keratoses.
1
Salamanca University, Salamanca, Spain, 2 Hospital Punta de Europa, Algeciras, Cádiz, Spain, 3 Pfizer, Madrid, Spain OBJECTIVES: To assess the association of conjunctival hyperaemia with the fixed combinations of latanoprost/timolol (LT/TM) and bimatoprost/timolol (BM/TM) in the treatment of ocular hypertension or glaucoma using a systematic review and metaanalyisis of randomized clinical trials (RCTs). METHODS: A systematic search for RCTs published between 2000 and 2009 was conducted in Medline, Embase and Controlled Trials Register databases. The outcome measured was the appearance of conjunctival hyperaemia in studies comparing the use of either LT/TM or BM/TM versus different therapeutic options. Statistical analysis was performed including the calculation of odds ratio (OR) and its respective confidence interval, along with the inter-trial statistical heterogeneity. A sensitivity analysis was also carried out. RESULTS: A total of 16 RCTs comparing LT/TM versus distinct therapeutic alternatives and 5 CT comparing BM/TM versus different therapeutic options fulfilled criteria to be included in the meta-analysis. Although heterogeneity of both comparisons was not very high in both the LT/TM group (Q 24.47; p 0.057; I 2 38.7 %) and the BM/TM group (Q 5.19; p 0.268; I 2 22.94 %) , the estimation of the OR by the random effects model was considered the most appropriate. According to this model the final OR for the LT/TM group was 0.56 (IC95%: 0.37-0.83), p 0.05 and for the BT/TM group the OR was 0.94 (IC95%: 0.66-1.34), p 0.05. In the sensitivity analysis performed, none of the RCTs included in this meta-analysis had an important effect in the global estimation of OR. CONCLUSIONS: According to available data, the use of LT/TM is associated with a significant reduction in the development of conjunctival hyperaemia versus the comparators used in the RCTs, whereas the use of BM/TM produces a conjunctival hyperaemia rate similar to its comparators.
PSS7 THE APPLICATION OF DISCRETE EVENT SIMULATION TO QUANTITATIVE RISK BENEFIT ANALYSIS
Maguire A 1 , Douglas I 2 , Blak BT 3 1 United BioSource Corporation, London, London, UK, 2 London School of Hygiene and Tropical Medicine, London, UK, 3 CSD EPIC, London, UK OBJECTIVES: To date, quantitative risk benefit has mainly involved the translation of Cost-Effectiveness techniques or utility adjusted epidemiological statistics. We aim to describe how Discrete Event Simulation "DES" offers the possibility of modelling the occurrence of several adverse events and beneficial events simultaneously whilst accounting for competing events. METHODS: Firstly, a longitudinal patient database is used to identify the target patient population. Secondly, incidence rates for the outcomes are calculated from the entire database, thereby providing the necessary granularity in terms of the predictive factors for the outcomes. The annual probability for each outcome is then assigned to each patient in the cohort and DES generates time to each event. Thereby the expected events for an unexposed patient cohort is created to which relative risks are applied to model drug exposure. An example using glaucoma patients is presented using data from The Health Improvement Network.
RESULTS:
We obtained data on 17,652 glaucoma patients who were known to be receiving glaucoma therapy at January 1, 2007. Patients were characterised according to the principal determinants of the outcomes (heart failure, asthma/COPD exacerbation). The same database provided general population incidence rates for the outcomes which were assigned to each patient according to their characteristics. National statistics provided death rates. The expected events over one year for a cohort of 10,000 glaucoma patients were: HF 95; asthma/COPD 143; deaths 605. CONCLU-SIONS: These expected numbers represent the occurrence of events in the natural history cohort. They were obtained by summing the outcome probabilities across the patient group. They do, however, represent the first step in creating a comprehensive method for risk-benefit quantification via DES and large patient databases; benefit can be modelled if expressed as the occurrence of an event. The method will need to incorporate uncertainty in all the input parameters and to update the probabilities after an event has occurred.
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COSTS-OF-ILLNESS OF ULCUS CRURIS IN GERMANY: RESULTS OF TWO APPROACHES
Purwins S 1 , Augustin M 1 , Herberger K 1 , Debus S 2 , Rustenbach SJ 1 1 University Clinics of Hamburg, Hamburg, Germany, 2 Asklepios Klinik Harburg, Hamburg, Germany OBJECTIVES: Estimation of cost-of-illness (COI) of leg ulcers in two German crosssectional studies using different methodical approaches. METHODS: A direct and an indirect method for cost estimation were utilized. In a nationwide cross-sectional study in 33 specialized dermatological, surgical and general-medical wound centres, resource consumption and associated costs of venous leg ulcer(s) were collected directly from physicians and patients. In a second cross-sectional regional study, involving 147 institutions (hospitals, residencies, nursing services, dermatological offices, services for homeless and addictives) treating patients with ulcus cruris, resource consumption and associated costs were inferred from history, wound condition and actual/previous treatments based on standardized cost categories. Main economic parameters in both studies were direct, indirect and intangible costs (health related quality of life, HRQoL) from the societal perspective. RESULTS: The national study enrolled n 218 patients with a mean age of 69.8 years (regional study: n 502, 71 years). Wounds existed for 7 (regional 9) years on average. The mean total COI per year and patient was a9,569 (a10,624). While direct costs summed up to a8658 (a9851), indirect costs were much lower a911 (a772). Of direct costs, a7631 (a9122) were covered by the Statutory Health Insurances (SHI) and a1027 (a730) by the patients. For SHI, major cost factors were inpatient costs, non-drug treatments and physicians/nurses fees. Moreover, clinical predictors such as wound size, number and duration as well as wound etiology and characteristics of care (quality, support) were identified. All patients were severely impaired in their HRQoL, implying a high burden of disease and relevant intangible costs. CONCLUSIONS: Chronic leg ulcers generate highly relevant COI. Despite different recruitment and cost estimation methods, both studies resulted in comparable direct, indirect and intangible costs; observed differences can be attributed to sample characteristics. The results point to early and qualified disease management in all related health services areas. To estimate the direct and indirect costs of occupational severe chronic hand eczema (OSCHE) in patients refractory to topical corticosteroids from the perspective of employer's mutual insurance companies (EMIC) in Spain. METHODS: An employer's mutual insurance company in Spain usually covers 75% of salaries and 100% of medical treatments of patients on occupational sick leave. A decision analytic model was developed to perform a cost analysis of OSCHE in patients refractory to topical corticosteroids from an employer's mutual insurance company perspective over a one year time horizon. A structured questionnaire was elaborated and answered by a Spanish panel of four dermatologists and two occupational physicians, to identify therapeutic management and estimate the use of resources associated to OSCHE. The clinical information was obtained from published literature and was complemented by physicians. The information regarding costs associated to the different types of disability was obtained from data of 156 patients from one of the main EMIC in Spain. Disabilities are classified by EMIC in three groups according to the time spent on sick leave: Partial disability (3 months), partial permanent disability (24 months) and total permanent disability (limited to current profession). RESULTS: Annual total costs of OSCHE for a Spanish EMIC were on average over a60,000 per patient. Direct costs represented 1.4% and indirect costs 98.6% of total costs. Total permanent disability was the most important cost driver, representing 69.3% of total costs, although only 18% of patients were estimated to reach this type of disability. CONCLUSIONS: Disability is the most important predictor of total costs in patients with OSCHE for the EMIC in Spain. Indirect costs are by far the most important cost driver (98.6%) for this disease. An effective therapy for OSCHE may significantly reduce the number of disabilities and therefore indirect costs. 1 Cemka, Bourg La Reine, France, 2 Cemka, Bg la reine, Hauts de Seine, France, 3 ALCON, Puurs, Belgium, 4 Oblikue Consulting, Barcelona, Spain, 5 Ars Accessus Medica/Erasmus University Rotterdam, Amsterdam, The Netherlands, 6 Abacus, Londen, UK OBJECTIVES: This study estimated the economic consequences of topical moxifloxacin compared with topical ofloxacin in the treatment of acute infectious conjunctivitis in Scotland (SC), Spain (ES) and The Netherlands(NL). METHODS: The rates of treatment failure, defined as no improvement or worsening symptoms, were estimated by a meta-analysis of randomized controlled trials (RCT) of moxifloxacin. The resources consumed and costs of treatment failure were assessed by a survey of 39 General Practitioners (GP) and 14 Ophthalmologists (OPH). National databases were used to estimate resource costs. The potential economic benefit was estimated, and sensitivity analyses were performed using moxifloxacin's failure rate advantage from trials directly comparing the drugs and meta-analysis of patients with confirmed bacterial infection (from 3.3% to 6.5% lower). RESULTS: Treatment failure costs are driven by extra physician consultations,and bacterial cultures. The average cost of a treatment failure in ES, SC and NL respectively is a38, a72, a53 when managed by a GP compared to OPH estimates of a108, a133, and a215. OPH extremes were a93 to a279a. Assuming 1.5% of the population experiences acute infectious conjunctivitis and a 10% failure rate in symptomatic improvement in control group patients, the estimated annual cost of failure ranges from a57,000a to a322,500 per million inhabitants. Primarily OPH use the studied drugs. With 4.7% less treatment failure when moxifloxacin instead of ofloxacin is used by OPH, the economic benefit was estimated at a5.1, a6.3, a10.13 per patient in ES, SC and NL respectively. This is a cost saving of approximately 11% on specialist treatment independent of the country. Sensitivity analysis resulted in an economic benefit from a3.58 to a14.01 as extremes of all countries. CONCLUSIONS: The decrease of treatment failure rate using moxifloxacin instead of ofloxacin in acute infectious conjunctivitis provides an economic benefit in three countries of interest.
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COSTS OF PATIENTS WITH OCCUPATIONAL SEVERE CHRONIC HAND ECZEMA REFRACTORY TO TOPICAL CORTICOSTEROIDS FOR EMPLOYER'S MUTUAL INSURANCE COMPANIES IN SPAIN
